Imipramine and EEG sleep in children with depressive symptoms.
Depression in children is currently an area of considerable controversy, as is the use of potent psychopharmacologic agents in children. Since EEG sleep techniques have proven to be useful in understanding the mechanisms of depression in adults and in predicting their response to antidepressants, a pilot study employing these techniques was undertaken in a population of hospitalized children. The EEG sleep of 12 children with significant depressive symptomatology was first examined after a two-week drug-free period and again approximately three weeks later when an optimum dose of imipramine had been maintained for at least 7 -- 10 days. Changes in sleep continuity, as reflected in increased wakefulness and a decreased sleep efficiency, as well as an increase in Stage 2 and a decrease in Stage 4 sleep, were observed throughout the entire sample. REM suppression was also noted, but tended to be most pronounced in those children who improved on imipramine.
D000293:Adolescent; D002648:Child; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology*; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007099:Imipramine / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D012890:Sleep / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects; D013997:Time Factors
D007099:Imipramine